share_log

8-K: Current report

8-K: Current report

8-K:重大事件
美股SEC公告 ·  2024/08/24 04:33

Moomoo AI 已提取核心信息

Ensysce Biosciences received a delisting notice from Nasdaq on August 20, 2024, due to non-compliance with the minimum stockholders' equity requirement of $2.5 million as of June 30, 2024. The company faces potential removal from the Nasdaq Stock Market unless it addresses this listing deficiency.The company plans to request a hearing before the Nasdaq Hearings Panel, which will temporarily stay any delisting action pending the hearing process. While Ensysce intends to explore options to regain compliance, there is no guarantee that the Panel will grant an extension or that the company will successfully meet the listing requirements within any granted extension period.
Ensysce Biosciences received a delisting notice from Nasdaq on August 20, 2024, due to non-compliance with the minimum stockholders' equity requirement of $2.5 million as of June 30, 2024. The company faces potential removal from the Nasdaq Stock Market unless it addresses this listing deficiency.The company plans to request a hearing before the Nasdaq Hearings Panel, which will temporarily stay any delisting action pending the hearing process. While Ensysce intends to explore options to regain compliance, there is no guarantee that the Panel will grant an extension or that the company will successfully meet the listing requirements within any granted extension period.
Ensysce Biosciences于2024年8月20日收到了纳斯达克的退市通知,原因是截至2024年6月30日未能满足250万美元的最低股东权益要求。公司面临被纳斯达克证券市场移除的潜在风险,除非它解决此上市缺陷。公司计划请求在纳斯达克听证委员会前进行听证,这将暂时中止任何退市行动,直至听证过程结束。虽然Ensysce打算探索期权以恢复合规性,但没有保证听证委员会会批准延期或公司能在任何批准的延期期间成功满足上市要求。
Ensysce Biosciences于2024年8月20日收到了纳斯达克的退市通知,原因是截至2024年6月30日未能满足250万美元的最低股东权益要求。公司面临被纳斯达克证券市场移除的潜在风险,除非它解决此上市缺陷。公司计划请求在纳斯达克听证委员会前进行听证,这将暂时中止任何退市行动,直至听证过程结束。虽然Ensysce打算探索期权以恢复合规性,但没有保证听证委员会会批准延期或公司能在任何批准的延期期间成功满足上市要求。
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息